Trial Purpose

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Learn More on



When speaking to your doctor, please have the trial identifier number available.

About The Study

This is an open label study, which means both you and the study doctor will know what you are getting. All patients who enrol in the trial will receive medication while on the study.*

100% will receive olaparib

*Patients must be centrally confirmed as HRR mutated, HRD positive or BRCA mutated and meet all other I/E criteria to enrol in the trial.

Trial Phase Icon

Phase 2

Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.

Trial start Icon


  • Actual study start date 12 December 2018
  • Estimated primary completion date 1 December 2025
  • Estimated study completion date 1 December 2025


Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon


Advanced Solid Neoplasms

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon



Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.